Cancer Immunotherapy and Biomarkers

This study identifies FGF21-driven lipolysis in cancer-associated adipocytes as a mechanism causing CD8+T cell dysfunction, showing that targeting this process can enhance cancer immunotherapy.

This study uses spatial transcriptomics to identify CD8+ T cell-driven mechanisms of kidney damage in ICI-AIN, showing increased IFN-γ signaling and proinflammatory myeloid cell activation.

The paper develops computational tools to identify cancer-reactive T cells and neoantigen-specific TCRs, showing their variability across cancer types and predictive value for immunotherapy response.

The paper compiles HLA typing and expression data for 287 pediatric cancer cell lines to support immunotherapy research and personalized treatment development.

This study shows that CRISPR suppression of NUTM1 promotes differentiation and increases TROP2 in NUT carcinoma cells, enhancing immunocytokine response and improving clinical outcomes.

This study shows that targeting drug-sensitive cancer cells with G12Ci inhibitors and combining it with immune therapies can eliminate drug-resistant subclones through immune-mediated bystander killing.

This study examines how CD8 T cells with different metabolic profiles contribute to tumor cure in hot versus cold murine tumors using radio-immunotherapy.

The paper identifies neuronal mimicry in cancer-associated fibroblasts driven by calcium waves, leading to immune exclusion, and shows that blocking this process restores immune control.

This paper identifies microbial transcriptional reprogramming in tumors that generates tumor-specific epitopes, enhancing immunotherapy safety by enabling targeted T cell responses.

This study identifies a transcriptomic signature predicting CD8+ T cell clone expansion rates and shows LAG-3 blockade reactivates this signature to re-expand contracted clones in tumors.

This study shows that dimethyl fumarate (DMF) enhances antitumor immunity in cervical cancer by reprogramming tumor cells to activate the mtDNA-cGAS-STING pathway, increasing CD8+ T cell infiltration.

This study shows CD8 T cells eliminate neoantigen+ epithelial stem cells in the colon, preventing cancer, without causing immunopathology.

The paper identifies crater-shaped structures in melanoma that enhance immune response to checkpoint blockade therapy in humans and zebrafish.

The paper provides a pan-cancer spatial analysis of immune biomarkers in the tumor microenvironment using multiplex immunofluorescence data from 2,019 tumors across 14 cancer types.

This study uses gene regulatory network and trajectory inference to analyze single-cell RNA-seq data from squamous cell carcinoma, revealing how PD-1 blockade reprograms T cell states and identifies key transcriptional regulators.

This study identifies two immune archetypes in HRD tumors—immune-inflamed and immune-evasive—linked to chromosomal instability and lineage, informing biomarker-driven therapies.

The paper identifies somatic TYK2 mutations in TILs that enhance anti-cancer immunity and shows their therapeutic potential through mouse models.

This study uses single-cell transcriptomics and TCR profiling to identify the transcriptional program governing cell fate decisions in neoantigen-specific CD8+ T cells and its clinical relevance.

This study shows that combining MCL1 and caspase inhibition enhances anti-tumor immunity in breast cancer by activating the cGAS-STING pathway and remodeling the tumor microenvironment.

This study identifies Bhlhe40 as a key regulator of T cell effector differentiation, showing distinct roles in CD4 and CD8 T cells for anti-PD-1 and anti-CTLA-4 therapies.

This study identifies B cell-derived extracellular vesicles and miR-99a-5p as key regulators of melanoma response to immunotherapy.

This study identifies TAK1 as a therapeutic target in pancreatic cancer that enhances anti-tumor immunity and sensitizes tumors to checkpoint blockade.

This study examines the dynamic changes in the immune microenvironment of paediatric solid tumours over time, revealing a shift toward immunosuppressive and tolerogenic states.

This study shows that UNG deficiency in tumor cells reduces intrinsic inflammatory signaling and alters interferon sensitivity, leading to a modified tumor microenvironment.

This study shows that radiation-induced podoplanin-positive fibroblasts limit CD8+ T-cell access to tumour cells, reducing radiotherapy effectiveness, and that disrupting PDPN signaling enhances tumour control.

This study identifies BPU11, a small molecule CD28 antagonist that disrupts CD28-B7 interactions and suppresses T-cell activation, offering a new approach to immune checkpoint blockade.

The paper compares radiation response in autochthonous and transplant sarcomas in mice with and without adaptive immunity, finding higher cure rates in transplant tumors with immune function.

The paper analyzes ORF1p expression across cancers, finding it correlates with immune suppression in some tumors and activation in others, linked to copy number alterations.

The paper identifies ETV4 as a transcription factor that restricts cytotoxic exhausted CD8+ T cell differentiation and shows CD74+ Tex cells correlate with improved survival.

This study shows liver metastases reduce checkpoint inhibitor efficacy by increasing splenic granulopoiesis and S100A9hi neutrophils, which suppress T-cell responses, and demonstrates that targeting S100A9 restores efficacy.